Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024 BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering of...

Algoma Steel Provides Fiscal Second Quarter 2025 Guidance SAULT STE. MARIE, Ontario, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of hot and cold rolled steel...

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024 DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...